在高危前列腺癌患者中, 添加酶胺剂在激素治疗中可将死亡风险降低40%, Adding enzalutamide to hormone therapy cut death risk by 40% in high-risk prostate cancer patients, a major treatment advance.

一项涉及17个国家的1,000多名男子的临床试验发现,在标准激素疗法中添加了酶氨酸盐,使那些在手术或辐射后患有高风险、复发性前列腺癌的人的死亡风险降低了40%。 A clinical trial involving over 1,000 men from 17 countries found that adding enzalutamide to standard hormone therapy reduced the risk of death by 40% in those with high-risk, recurrent prostate cancer after surgery or radiation. 该研究报告发表在《新英格兰医学杂志》上,并提交ESBO大会。 该研究报告显示,接受混合疗法的病人在8年之后,存活率有了显著改善。 The study, published in The New England Journal of Medicine and presented at the ESMO Congress, showed significantly improved survival after eight years for patients receiving the combination. 研究人员将结果称为一项重大进步,因为先前的治疗并未使这一群体存活下去。 Researchers called the results a major advance, as prior treatments had not extended survival for this group. 预计调查结果将重塑治疗准则,有可能使这种综合成为新的护理标准。 The findings are expected to reshape treatment guidelines, potentially making the combination the new standard of care.